Downregulation of ERp57 expression is associated with poor prognosis in early-stage cervical cancer. (November 2013)

• Record Type: Journal Article
• Authors: Chung, Hyunsoo; Cho, Hanbyoul; Perry, Candice; Song, Jaekyung; Ylaya, Kris; Lee, Heejeong; Kim, Jae-Hoon
• Is Part Of: Biomarkers. Volume 18:Number 7(2013)
• Page Start: 573
• Page End: 579
• Publication Date: 2013-11
• Subjects: Biochemical markers -- Periodicals; 610.28
• DOI: 10.3109/1354750X.2013.827742
• Languages: English
• ISSNs: 1354-750X

Abstract

<abstract> <title>Abstract</title> <p> <italic>Objective</italic>: We investigated the clinical significance of ERp57 in the progression of cervical cancer.</p> <p> <italic>Methods</italic>: mRNA and protein expression of ERp57 in cervical neoplasias were examined.</p> <p> <italic>Results</italic>: ERp57 mRNA expression was significantly decreased in cervical cancers. Immunohistochemistry revealed that ERp57 expression in 123 cervical cancers was down-regulated compared to cervical intraepithelial neoplasias or normal tissues (<italic>p</italic> &lt; 0.001). Low ERp57 expression was significantly associated with worse overall survival (HR = 12.19, <italic>p</italic> = 0.018).</p> <p> <italic>Conclusions</italic>: Low ERp57 expression independently predicts a poor outcome for patients with cervical cancer, supporting the notion that ERp57 may be a promising novel cancer target.</p> </abstract>